-+ 0.00%
-+ 0.00%
-+ 0.00%

DiamiR To Highlight Potential Of Brain-Enriched, Inflammation-Associated microRNAs As Epigenetic Biomarkers Of Neurodegeneration At CTAD Conference

Benzinga·11/19/2025 13:05:14
Listen to the news

DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration.